Raptor Pharmaceuticals Corp. (RPTP)
-NasdaqGM 6.17 
0.51(7.63%) 4:00PM EDT|After Hours
:
6.17 0.00 (0.02%) 4:45PM EDT
| Prev Close: | 6.68 |
|---|
| Open: | 6.24 |
|---|
| Bid: | 5.95 x 900 |
|---|
| Ask: | 6.12 x 1000 |
|---|
| 1y Target Est: | 10.75 |
|---|
| Beta: | 0.13 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 5.90 - 6.46 |
|---|
| 52wk Range: | 4.35 - 7.67 |
|---|
| Volume: | 1,488,900 |
|---|
| Avg Vol (3m): | 651,420 |
|---|
| Market Cap: | 330.13M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.84 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Two Different Outlooks for Two Tuesday Performersat Motley Fool(Thu 5:20PM EDT)
- Raptor Pharmaceuticals downgraded to Neutral from Outperform at Wedbushtheflyonthewall.com(Thu 7:24AM EDT)
- Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic CystinosisPR Newswire(Wed, May 1)
- Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan DrugsWall Street Transcript(Wed, May 1)
- RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Wed, May 1)
- 3 Healthcare Stock Stories For Tuesday Portfolio Wellnessat Wall St. Cheat Sheet(Wed, May 1)
- Raptor's FDA Approval Is New Test For Orphan Drug Pricingat TheStreet(Wed, May 1)
- Why Raptor Pharmaceuticals Shares Spiked and Then Droppedat Motley Fool(Tue, Apr 30)
- 3 Pharmaceutical Companies Awaiting FDA Approval, Part IIat Seeking Alpha(Tue, Apr 30)
- Raptor Drug Wins U.S. Approval to Treat Rare Diseaseat Bloomberg(Tue, Apr 30)
- InPlay: Raptor Pharma confirms PROCYSBI receives FDA approval for the treatment of nephropathic cystinosisBriefing.com(Tue, Apr 30)
- Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic CystinosisPR Newswire(Tue, Apr 30)
- UPDATE 1-U.S. FDA approves Raptor's drug for nephropathic cystinosisat Reuters(Tue, Apr 30)
- Expert Analyst Ian Somaiya Discusses the Decline in European Drug Pricing with The Wall Street Transcript; Models a 1% to 2% Annual Decline in Price for Companies That Sell OverseasWall Street Transcript(Tue, Apr 30)
- 2 FDA Decisions You Can't Afford to Miss This Weekat Motley Fool(Sun, Apr 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. It engages in the research, manufacture, and commercialization of medicines to treat nephropathic cystinosis, non-alcoholic steatohepatitis (N...
View More